EstroG-100 Reduces Burden of MenopauseEstroG-100 Reduces Burden of Menopause

ANAHEIM, Calif.EstroG-100, a an herbal product containing a mixture of standardized extracts of Cynanchum wilfordii, Phlomis umbrosa and Angelica gigas from Helios CORP and its partner Sunbio, demonstrated benefits in menopausal women in two recent studies completed by the companies in December.

According to the companies, the first support study evaluated one group of women over the course of four weeks, looking at the speed of action within seven days and 28 days. The group consisted of 20 women consuming 517 mg/d of  EstroG-100. Within seven days, 50 percent of the women confirmed significant improvement in multiple symptoms such as hot flashes, vaginal dryness, vertigo, fatigue and insomnia. Eighty percent of the women showed improvement in these multiple symptoms after four weeks of consumption with EstroG-100.

In a previous study published at the end of 2011, EstroG-100 significantly improved the menopausal symptoms of pre-, peri- and post-menopausal women without weight gain or any serious side effects.

The second study was conducted over a period of six weeks with 30 women divided into three groups and consuming 517 mg/d of EstroG-100. One group took EstroG-100, one group used a popular facial cosmetic, and a third group took both the EstroG-100 and used the cosmetic product. Each group was evaluated for skin wrinkles, moisture, tone and blushing. Average improvement of all four categories was 50-percent greater than baseline in the group who took both EstroG-100 and used the cosmetic.

Currently EstroG-100 maintains a 12-month phase I human clinical study; a four-month, U.S.- based, phase II human clinical study, four toxicity studies, two cancer risk studies, two liver protective studies, and two non-estrogenicity studies.